KS trial begins.
D000163:Acquired Immunodeficiency Syndrome / Q000150:complications / Q000188:drug therapy*; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D017322:Clinical Trials, Phase II as Topic; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007211:Indoles / Q000008:administration & dosage*; D008297:Male; D015337:Multicenter Studies as Topic; D018579:Patient Selection; D011758:Pyrroles / Q000008:administration & dosage*; D012514:Sarcoma, Kaposi / Q000150:complications / Q000188:drug therapy*; D014481:United States
D020533:Angiogenesis Inhibitors; D007211:Indoles; D011758:Pyrroles; C116890:Semaxinib